Retinal diseases: the CATT Study and the emerging treatments
A difficult choice: lower costs vs. fewer side effects
Retinal diseases: the CATT Study and the emerging treatments
A difficult choice: lower costs vs. fewer side effects
The Novartis press conference addresses issues related to the treatment of degenerative diseases of the macula and retinal diseases and their impact on the quality of life. The CATT Study compares two different molecules (ranibizumab and bevacizumab), and focuses on the different side effects.
The Novartis press conference addresses issues related to the treatment of degenerative diseases of the macula and retinal diseases and their impact on the quality of life. The CATT Study compares two different molecules (ranibizumab and bevacizumab), and focuses on the different side effects.
presentations
Introduction - Susanna Petruni TG1 (RAI)
it
The impact of retinal diseases
it
Prof. Filippo Cruciani
Hyper vision and blindness
it
Prof. Filippo Cruciani
Macular Degeneration: impact on quality of life
it
Prof. Filippo Cruciani
Retinal diseases and economic social impact
it
Prof. Filippo Cruciani
Macular degeneration does not cause blindness
it
Prof. Francesco Bandello
Age related Macular Degeneration: the treatments
it
Prof. Francesco Bandello
C.A.T.T. Trial: the side effects
it
Prof. Francesco Bandello
Economic savings or minimum side effects: a difficult choice
it
Prof. Francesco Bandello
Questions & answers - 1st part
it
Questions & answers - 2nd part
it
Questions & answers - 3rd part
it
